CN109965104A - A kind of composition and its preparation method and application containing Sodium Hyaluronate - Google Patents
A kind of composition and its preparation method and application containing Sodium Hyaluronate Download PDFInfo
- Publication number
- CN109965104A CN109965104A CN201910252713.XA CN201910252713A CN109965104A CN 109965104 A CN109965104 A CN 109965104A CN 201910252713 A CN201910252713 A CN 201910252713A CN 109965104 A CN109965104 A CN 109965104A
- Authority
- CN
- China
- Prior art keywords
- sodium hyaluronate
- parts
- composition
- weight
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 142
- 229920002385 Sodium hyaluronate Polymers 0.000 title claims abstract description 140
- 229940010747 sodium hyaluronate Drugs 0.000 title claims abstract description 140
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title description 8
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 43
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims abstract description 27
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 19
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 19
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 19
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 239000002366 mineral element Substances 0.000 claims abstract description 13
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 30
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 26
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 26
- 239000004475 Arginine Substances 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 16
- 229930003316 Vitamin D Natural products 0.000 claims description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 16
- SWXXYWDHQDTFSU-UHFFFAOYSA-K chromium(3+);2-hydroxypropane-1,2,3-tricarboxylate Chemical class [Cr+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SWXXYWDHQDTFSU-UHFFFAOYSA-K 0.000 claims description 16
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 16
- 235000007079 manganese sulphate Nutrition 0.000 claims description 16
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical class [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 16
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- 235000015424 sodium Nutrition 0.000 claims description 16
- 235000019166 vitamin D Nutrition 0.000 claims description 16
- 239000011710 vitamin D Substances 0.000 claims description 16
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 16
- 229940046008 vitamin d Drugs 0.000 claims description 16
- 235000011478 zinc gluconate Nutrition 0.000 claims description 16
- 235000011009 potassium phosphates Nutrition 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical class [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 14
- 235000011086 calcium lactate Nutrition 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 13
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 13
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 12
- 229930182817 methionine Natural products 0.000 claims description 12
- 235000015921 sodium selenite Nutrition 0.000 claims description 12
- 229940042585 tocopherol acetate Drugs 0.000 claims description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- 239000011781 sodium selenite Substances 0.000 claims description 11
- 229960001471 sodium selenite Drugs 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- KFSJYZYQSZKRRQ-BYPYZUCNSA-N (2s)-2-(hydroxyamino)-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@H](NO)C(O)=O KFSJYZYQSZKRRQ-BYPYZUCNSA-N 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 238000009738 saturating Methods 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 19
- 239000011575 calcium Substances 0.000 abstract description 19
- 229910052791 calcium Inorganic materials 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 230000002265 prevention Effects 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 8
- 230000037182 bone density Effects 0.000 abstract description 7
- 206010003246 arthritis Diseases 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000033001 locomotion Effects 0.000 abstract description 5
- 230000001771 impaired effect Effects 0.000 abstract description 3
- 230000001050 lubricating effect Effects 0.000 abstract description 3
- 102000008186 Collagen Human genes 0.000 description 25
- 108010035532 Collagen Proteins 0.000 description 25
- 229920001436 collagen Polymers 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 18
- 229960005069 calcium Drugs 0.000 description 18
- 229940099596 manganese sulfate Drugs 0.000 description 14
- 239000011702 manganese sulphate Substances 0.000 description 14
- 229910000160 potassium phosphate Inorganic materials 0.000 description 14
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 13
- 239000013522 chelant Substances 0.000 description 13
- 229940064958 chromium citrate Drugs 0.000 description 13
- 239000011670 zinc gluconate Substances 0.000 description 13
- 229960000306 zinc gluconate Drugs 0.000 description 13
- 239000001527 calcium lactate Substances 0.000 description 12
- 229960002401 calcium lactate Drugs 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000012659 Joint disease Diseases 0.000 description 8
- 210000001188 articular cartilage Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960002442 glucosamine Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- -1 Hydroxyl methionine Chemical compound 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VUKOXQIVNYFVAY-RGMNGODLSA-N [Fe].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Fe].C(CC)N[C@@H](CCO)C(=O)O VUKOXQIVNYFVAY-RGMNGODLSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- SCWQRZHMKQEINE-UHFFFAOYSA-N selenous acid;sodium Chemical compound [Na].O[Se](O)=O SCWQRZHMKQEINE-UHFFFAOYSA-N 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- ZGBSOTLWHZQNLH-UHFFFAOYSA-N [Mg].S(O)(O)(=O)=O Chemical compound [Mg].S(O)(O)(=O)=O ZGBSOTLWHZQNLH-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001749 antrachitic effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- SMHNUIFHMAGAFL-UHFFFAOYSA-N calcium;2-hydroxypropanoic acid Chemical compound [Ca].CC(O)C(O)=O SMHNUIFHMAGAFL-UHFFFAOYSA-N 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 206010073767 Developmental hip dysplasia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007446 Hip Dislocation Diseases 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- JSXROLUNEDJZJE-UHFFFAOYSA-N acetic acid;phenol Chemical class CC(O)=O.OC1=CC=CC=C1 JSXROLUNEDJZJE-UHFFFAOYSA-N 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012476 oxidizable substance Substances 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000010419 pet care Methods 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of composition containing Sodium Hyaluronate, include the first Sodium Hyaluronate that molecular weight is 20KDa-150KDa, second of Sodium Hyaluronate, amino acid and the vitamin that molecular weight is 220KDa-1500KDa.Composition of the present invention containing Sodium Hyaluronate; it is compounded with second of Sodium Hyaluronate as main component using the first Sodium Hyaluronate; the Sodium Hyaluronate being capable of fine lubricating joint; cooperate amino acid, vitamin, mineral element and its complex compound, protein, gucosamine, sodium chondroitin sulfate, dimethyl sulfone and eicosapentaenoic acid; it is protected so that the composition integrates to replenish the calcium with joint; to arthritis, joint motions are impaired good prevention effect; it can also promote development, enhancing bone density simultaneously, improve the toughness and hardness of bone.
Description
Technical field
This application involves pet food technical fields, and relate more particularly to a kind of composition containing Sodium Hyaluronate and
Preparation method and application.
Background technique
Pet already becomes " associate member " in family, in people's recreation and amusement, release environmental pressure, promotes children's love
Important role is play on the heart, lonely, the help disabled person of mitigation old man etc., while playing irreplaceable role, pet
While bringing people's happy laughters and cheerful voices, paying close attention to its health problem also be can not be ignored.Due to house pet unlike in the Nature at
Long is similar with strong physique, and therefore, the various diseases of pet also become people's concern.Present pet joint
Disease has become one of most important disease of all kinds of pets, and pet joint disease enumerates hip dysplasia, bone moves back
Change, osteoporosis, protrusion of lumber intervertebral disc, various arthritis etc., though will not threat to life, the quality of life of pet can be allowed to beat greatly
Discount.
Hyaluronic acid is glued by the macromolecular acidity that D-Glucose aldehydic acid and N-acetylglucosamine dissacharide units form
Polysaccharide, is called sodium hyaluronate, and Columbia Univ USA's ophthalmology professor Meyer in 1934 etc. is isolated from bovine vitreous body first
The substance.Hyaluronic acid shows a variety of important physiological functions with its unique molecular structure and physicochemical property in body,
Such as lubricating joint, the permeability of vascular wall, regulatory protein matter, Water-Electrolyte diffusion and operating are adjusted, wound healing etc. is promoted.
Drug currently used for osteoarthritis is mainly non-steroid anti-inflammatory drug, has anti-inflammatory and analgesic effect, is suitble to inflammation
Disease property pain；But this kind of drug will lead to Nausea and vomiting etc. alimentary canal discomfort, long-time service also will increase hemorrhage of digestive tract
Risk.And the treatment methods such as this traditional detumescence, analgesic, it can only treat the symptoms, it is difficult to it effects a permanent cure, and currently on the market, it is right
Also comparing shortcoming in the drug of prevention pet joint disease, some pet care product prices are also more expensive, and effect is less obvious,
Therefore the composition for studying a kind of cheap, eutherapeutic prevention pet joint disease is one of the field urgent problem to be solved.
Summary of the invention
In order to solve the above-mentioned technical problem, the application is proposed.This application provides a kind of combinations containing Sodium Hyaluronate
Object can prevent pet joint disease using pet food prepared by the composition, and curative effect is preferable.
To achieve the above object, the present invention adopts the following technical scheme that.
1, a kind of composition containing Sodium Hyaluronate, which is characterized in that comprising molecular weight be 20KDa-150KDa first
Kind Sodium Hyaluronate, second of Sodium Hyaluronate, amino acid and the vitamin that molecular weight is 220KDa-1500KDa.
2, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that the first Sodium Hyaluronate
Molecular weight is 20KDa-100KDa；Preferably, the molecular weight of the first Sodium Hyaluronate is 20KDa-80KDa；Further
Preferably, the molecular weight of the first Sodium Hyaluronate is 20KDa-60KDa.
3, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that second of Sodium Hyaluronate
Molecular weight is 250KDa-1000KDa；Preferably, the molecular weight of second of Sodium Hyaluronate is 250KDa-800KDa；Into
Preferably, the molecular weight of second of Sodium Hyaluronate is 300KDa-600KDa to one step.
4, containing the composition of Sodium Hyaluronate according to item 2 or 3, which is characterized in that relative to 100 weight of total weight
The total content of the composition of part, the first described Sodium Hyaluronate and second of Sodium Hyaluronate is 0.1-4 parts.
5, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that relative to 100 parts by weight of total weight
Composition, the content of the first Sodium Hyaluronate is 0.05-2 parts；Preferably, the first Sodium Hyaluronate contains
Amount is 0.05-1.5 parts；It is further preferred that the content of the first Sodium Hyaluronate is 0.05-1 parts.
6, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that relative to 100 parts by weight of total weight
Composition, the content of second of Sodium Hyaluronate is 0.05-2 parts, it is preferable that second of Sodium Hyaluronate contains
Amount is 0.05-1.5 parts；It is further preferred that the content of second of Sodium Hyaluronate is 0.05-1 parts.
7, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that the composition further includes albumen
Matter, gucosamine, sodium chondroitin sulfate, dimethyl sulfone and eicosapentaenoic acid；Combination relative to 100 parts by weight of total weight
Object, the content of the protein are 15-30 parts, and the content of the gucosamine is 5-10 parts, and the sodium chondroitin sulfate contains
Amount is 1-20 parts, and dimethyl sulfone is 1-15 parts and eicosapentaenoic acid is 1-20 parts.
8, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that the amino acid be selected from histidine,
At least one of methionine, hydroxyl methionine, lysine or arginine；Relative to the composition of 100 parts by weight of total weight, institute
The total content for stating amino acid is 1-10 parts.
9, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that the vitamin is selected from dl- α-life
Educate at least one of phenol acetic acid esters or vitamin D；Relative to the composition of 100 parts by weight of total weight, the vitamin it is total
Content is 5-20 parts.
10, containing the composition of Sodium Hyaluronate according to item 1, which is characterized in that the composition further includes mineral
Element and its complex compound, relative to the composition of 100 parts by weight of total weight, the mineral element and its complex compound include: 0.5-3
Part calcium lactate, 0.1-1 parts of magnesium sulfate, 0.1-1.5 parts of histidine iron network chelates, 0.1-1 parts of zinc gluconates, 0.05-0.5 parts
The sub- selenium of copper sulphate, 0.05-0.3 part potassium phosphate, 0.03-0.5 parts of manganese sulfates, 0.01-0.5 parts of chromium citrates and 0.01-0.5 parts
Sour sodium.
11, containing the composition of Sodium Hyaluronate according to item 7, which is characterized in that the protein is collagen.
12, a kind of preparation method containing the composition containing Sodium Hyaluronate described in any one of item 1-11, feature
It is, includes the following steps:
Second of hyaluronic acid of 220KDa-1500KDa is added in the first Sodium Hyaluronate of 20KDa-150KDa
Sodium, amino acid, vitamin, mineral element and its complex compound, protein, gucosamine, sodium chondroitin sulfate, dimethyl sulfone and
Eicosapentaenoic acid is uniformly mixing to obtain the composition containing Sodium Hyaluronate.
13, a kind of to contain the answering in pet food of the composition containing Sodium Hyaluronate described in any one of item 1-11
With.
14. a kind of pet food contains the composition described in any one of 1-11 containing Sodium Hyaluronate or contains
There is the composition using the preparation of preparation method described in item 12.
Composition of the present invention containing Sodium Hyaluronate, using the first Sodium Hyaluronate and second of hyaluronic acid
Sodium compounding is used as main component, and the Sodium Hyaluronate can lubricate very well, Saving cortilage, cooperates amino acid, vitamin, mineral
Element and its complex compound, protein, gucosamine and sodium chondroitin sulfate are protected so that the composition collection is replenished the calcium with joint
It is integrated, to arthritis, joint motions are impaired good prevention effect, while can also promote development, enhancing bone density, improve
The toughness and hardness of bone.
The specific embodiment of invention
Composition provided by the invention containing Sodium Hyaluronate is transparent for the first of 20KDa-150KDa comprising molecular weight
Matter acid sodium, second of Sodium Hyaluronate, amino acid and the vitamin that molecular weight is 220KDa-1500KDa.Sodium Hyaluronate is
The main component for constituting articular cartilage and synovia plays lubrication, nutrition, moisturizing and protective effect to articular cartilage, and can
Mitigate reaction in inflamed joint, promotes the effect of endogenous hyaluronic acid secretion.The first Sodium Hyaluronate is a kind of glucan
Aldehydic acid, without species specificity, it is widely present in the tissue such as placenta, amniotic fluid, crystalline lens, articular cartilage, dermal layer of the skin；Device
It is distributed in cytoplasm, in cytoplasm in official, plays lubrication and nourishing effect to cell and crganelle official itself contained therein,
The microenvironment of cell metabolism is provided simultaneously, the first Sodium Hyaluronate can penetrate into corium, have mild dilation capillary, increase
Blood circulation improves intermediate supersession, promotes skin-nourishing absorption, has the function of stronger wrinkle-chasing, can increase skin elasticity,
Delay skin aging；The first Sodium Hyaluronate can also promote the proliferation and differentiation, scavenging activated oxygen of epidermal cell, can prevent
With reparation skin injury.Second of Sodium Hyaluronate plays a protective role in skin surface, keeps skin smooth wet.
In a specific embodiment, the molecular weight of the first Sodium Hyaluronate is 20KDa-100KDa；It is excellent
Selection of land, the molecular weight of the first Sodium Hyaluronate are 20KDa-80KDa；It is further preferred that the first described hyalomitome
The molecular weight of sour sodium is 20KDa-60KDa.
In a specific embodiment, the molecular weight of second of Sodium Hyaluronate is 250KDa-1000KDa；It is excellent
Selection of land, the molecular weight of second of Sodium Hyaluronate are 250KDa-800KDa；It is further preferred that described second transparent
The molecular weight of matter acid sodium is 300KDa-600KDa,
In a specific embodiment, the composition relative to 100 parts by weight of total weight, second of hyaluronic acid
The total content of sodium and the first Sodium Hyaluronate is 0.1-4 parts.
In a specific embodiment, the composition relative to 100 parts by weight of total weight, second of hyaluronic acid
The content of sodium is 0.05-2 parts；Preferably, the content of second of Sodium Hyaluronate is 0.05-1.5 parts；Further preferably
Ground, the content of second of Sodium Hyaluronate are 0.05-1 parts.
In a specific embodiment, the composition relative to 100 parts by weight of total weight, the first described hyalomitome
The content of sour sodium is 0.05-2 parts, it is preferable that the content of the first Sodium Hyaluronate is 0.05-1.5 parts；Further preferably
Ground, the content of the first Sodium Hyaluronate are 0.05-1 parts.
In a specific embodiment, the composition relative to 100 parts by weight of total weight, molecular weight 300KDa-
The content of second of Sodium Hyaluronate of 600KDa is 0.05-1 parts, and molecular weight is the first hyaluronic acid of 20KDa-60KDa
The content of sodium is 0.05-1 parts, and the composition compounded is capable of the joint disease of more effectively pre- anti-pet.
In a specific embodiment, the composition further includes mineral element and its complex compound, protein, grape
Osamine and sodium chondroitin sulfate；Relative to the composition of 100 parts by weight of total weight, the content of the protein is 15-30 parts,
The content of the gucosamine is 5-10 parts, and the content of the sodium chondroitin sulfate is 1-20 parts；The content of dimethyl sulfone is 1-
15 parts, the content of eicosapentaenoic acid is 1-20 parts.Being for pet mineral element and its complex compound can not itself generation, synthesis
, need to obtain from food daily, these mineral elements and its complex compound be present in always body fluid, blood, muscle, bone,
Among alimentary canal, plays and maintain body fluid pervious pressure constant and the important function of pH value balance；Protein is the substance base of life
Plinth is organic macromolecule, is the basic organic matter for constituting cell, is the main undertaker of vital movement.Gucosamine also known as ammonia
Base glucose is a kind of natural amino monosaccharide, has physiological activity, be the weight of proteoglycan in articular cartilage matrix and synovia
Want component part.It can specifically act on articular cartilage, restore the normal metabolic function of cartilage cell, and stimulation cartilage is thin
Born of the same parents generate the proteoglycan of physiological, promote the synthesis of collagen in cartilage matrix, safeguard the morphosis of articular cartilage.It is soft
Bone is mainly that " sulfate radical " is leaned on to mediate to the absorption of Glucosamine, the important component of " sulfate radical " is contained in joint, simultaneously
Sodium chondroitin sulfate has " sulfate radical ", can be enhanced absorption of the cartilage for Glucosamine, thus in Glucosamine and
The simultaneous composition of sodium chondroitin sulfate, it is preferable to arthritic prevention effect；Dimethyl sulfone is a kind of organic sulfur compound,
It is the necessary material of human collagen albumen synthesis.All contain two in the skin of people, hair, nail, bone, muscle and each organ
Methyl sulfone, once health disorders or generation disease will be caused by lacking.Therefore, external to be widely applied as health medicine；.20
Carbon 5 alkene acid has reducing blood lipid, blood pressure lowering, hypoglycemic effect, can prevent and improve artery sclerosis, prevent hypertension and prevention
The functions such as rheumatic arthritis.
In a specific embodiment, the amino acid be selected from histidine, methionine, hydroxyl methionine, lysine or
At least one of person's arginine；Relative to the composition of 100 parts by weight of total weight, the total content of the amino acid is 1-10
Part.When the type of the amino acid is a kind of, content is 1-10 parts, when the type of the amino acid is two kinds or more of
When, the total amount of each amino acid is 1-10 parts.Amino acid provides not only the important of synthetic proteins matter in the intracorporal presence of pet
Raw material, and for promoting to grow, progress eubolism, sustaining life provides material base.If lack in pet body or
Wherein a certain kind is reduced, the normal life metabolism of pet just will receive obstacle, and generation or the life for even resulting in various diseases are living
It is dynamic to terminate.Histidine can be used as biochemical reagents, can be used for treating heart disease, anaemia, the diseases such as rheumatic arthritis, and its
It is particularly important during growth of animal；Histidine can also reduce gastric acidity, mitigate the pain of gastrointestinal procedures, and the mitigation gestational period vomits
It spits and scorching hot sense, inhibition alimentary canal as caused by vegetative nerve anxiety festers, also have to anaphylactia, such as asthma
Effect.In addition, the expansible blood vessel of histidine, reduces blood pressure, the clinically treatment for diseases such as angina pectoris, cardiac insufficiencies；
Histidine content substantially reduces in patient with rheumatoid arthritis blood, using finding its grip after histidine, walk with erythrocyte sedimentation rate etc.
Index take a favorable turn.Methionine is one of essential amino acid of pet, participates in protein synthesis, because it itself cannot give birth in vivo
At so, if methionine deficiency will lead to vivo protein biosynthesis block, body damage must be caused by outside acquisition.
Lysine provides structural constituent for synthetic carnitine, and carnitine can promote the synthesis of fatty acid in cell.It is added into food a small amount of
Lysine, can stimulate the secretion of pepsin and gastric acid, improve gastric secretion effect, play and improve a poor appetite, promote to grow
With development.Lysine can also improve the absorption and its accumulation in vivo of calcium, accelerate bone growth.Hydroxyl methionine be livestock and poultry must
Amino acid is needed, hydroxyl methionine is lacked, depauperation, weight loss, hepatic and renal function decrease, muscular atrophy, fur can be caused rotten
Etc. diseases.Arginine is a constituent in ornithine circulation, has extremely important physiological function, eats arginine more,
Arginic activity in liver can be increased, help the ammonia in blood being changed into urea and excreted out, so, arginine
To hyperammonemia, hepatic dysfunction etc. is powerful；Arginine is also the main component of sperm protein, there is the matter for promoting sperm
Amount improves the effect of sperm motility energy；In addition arginine or a kind of biradical amino acid, some situations such as body development not
Mature or under serious stressed condition, if lacking arginine, body just cannot maintain positive nitrogen equilibrium and normal physiological function,
Animal experiments show that after rat is injured, if the arginine in kind food is less than 0.05%, rat just cannot maintain nitrogen balance with just
It is frequently grown, if the at this moment arginine of supplement 1%, preferable to the recovery of injured rat.
In a specific embodiment, the vitamin in dl- alpha-tocopherol acetate or vitamin D extremely
Few one kind；Relative to the composition of 100 parts by weight of total weight, the content of the vitamin is 5-20 parts.Dl- alpha-tocopherol acetic acid
Ester also known as vitamin E prevent the readily oxidizable substances such as cell membrane and intracellular unsaturated fatty acid during body metabolism
It is oxidized, to protect the complete of cell membrane and then prevent the effect of aging, is able to maintain the normal function of reproductive organs, vitamin
E has stronger reproducibility, can be used as antioxidant, as internal antioxidant, eliminates interior free yl, reduces the wound of ultraviolet light
Evil.Vitamin D is sterol analog derivative, has anti-rachitic effect, also known as antirachitic vitamin.It is now recognized that vitamin D
It is a kind of steroid hormone, most important member is VD2 (ergocalciferol) and VD3 (gallbladder calcification in vitamin D family member
Alcohol).Vitamin D is derivative of the different provitamin Ds after ultraviolet irradiation, and absorption of the human body to calcium, phosphorus can be improved；
Promote growth and bone calcification, promotes tooth sound；But also the absorption of phosphorus can be increased by intestinal wall, and increase by renal tubule
Add the re-absorption of phosphorus；Prevent amino acid from losing by kidney.
In a specific embodiment, the composition further includes mineral element and its complex compound, relative to gross weight
Measure the composition of 100 parts by weight, the mineral element and its complex compound include: 0.5-3 parts of calcium lactates, 0.1-1 parts of magnesium sulfate,
0.1-1.5 parts of histidine iron network chelates, 0.1-1 parts of zinc gluconates, 0.05-0.5 parts of copper sulphate, 0.05-0.3 parts of phosphoric acid
Potassium, 0.03-0.5 part manganese sulfate, 0.01-0.5 parts of chromium citrates and 0.01-0.5 parts of sodium selenites." sulfate radical " can promote
Absorption of the cartilage to Glucosamine, calcium are bone constituents, can transmit nerve signal, and calcium and phosphorus one work energy
Strong bone promotes pet growth；Zinc helps to maintain the health of skin and coat；The adjustable water salt balance of potassium participates in energy
Amount metabolism；Magnesium is the constituent of bone, related with nervous system and energetic supersession；Iron is erythrocyte constituent,
Participate in cellular respiration；Copper is red blood cell and bone constituent；Sodium energy statocyte, manganese, chromium, selenium are necessary in pet body
Microelement.
In a specific embodiment, the protein is collagen；Bone collagen is the one of animal tissue
Kind of special construction albumen is bone, the important component in cartilaginous tissue, wherein II type ossein is the master in articular cartilage
Want collagen component, the 90~95% of the total collagen quantity of Zhan.TypeⅡ Collagen forms three-dimensional spiral structure by 3 identical α chains,
And by covalently cross-linked, special space network is formed.II Collagen Type VI is combined closely with proteoglycan in cartilage, jointly
The unique functionality of cartilage is constituted, to the integrality important role for keeping cartilage structure.II Collagen Type VI and proteoglycan
The change of quality and quantity is the immediate cause that articular cartilage loses its normal biomechanical characteristic, and variation has close with osteoarthritis
Cut relationship.TypeⅡ Collagen can more maintain cellular morphology, extend the time that dedifferen tiation occurs, and more conducively cell divides again
Change.In addition, the coagulator of collagen or calcium, no collagen is calcareous cannot to be sticked and is solidificated in bone, only intake foot
Enough collagens, pet can preferably utilize the calcium of intake, can effectively maintain bone density, increase itself bone
Robustness, improve symptoms of joint pain and pre- anti-osteoporosis.
In a specific embodiment, the preparation side of a kind of composition containing Sodium Hyaluronate provided by the present invention
Method includes the following steps:
Amino acid, vitamin, mineral element and its complex compound, egg are added in the Sodium Hyaluronate of 20KDa-1500KDa
White matter, gucosamine, sodium chondroitin sulfate, dimethyl sulfone and eicosapentaenoic acid are uniformly mixing to obtain described containing transparent
The composition of matter acid sodium.The composition containing Sodium Hyaluronate of method preparation through the invention has prevention well
Joint disease promotes the advantages that development, the absorption of enhancing calcium.
In a specific embodiment, a kind of answering in pet food of the composition containing Sodium Hyaluronate
With, the composition can be added in pet food, prevention or treatment joint disease.
Composition of the present invention containing Sodium Hyaluronate, using the first Sodium Hyaluronate and second of hyaluronic acid
Sodium compounding is used as main component, and the Sodium Hyaluronate can lubricate very well, Saving cortilage, but also is resistant to oxidation retardant and declines
Always, cooperate each amino acid, vitamin, mineral element and its complex compound, protein, gucosamine, sodium chondroitin sulfate, diformazan
Base sulfone and eicosapentaenoic acid so that the composition integrate replenish the calcium and joint protection, to arthritis, joint motions by
Damage has good prevention effect, while can also promote growth, development, the absorption for promoting calcium, enhancing bone density, improves the tough of bone
Property and hardness.The composition is added in pet food, can be used as daily health products.
Following embodiment of the invention is only used to illustrate realization a specific embodiment of the invention, these embodiments cannot
It is not understood as limitation of the present invention.It is other it is any change made by without departing from the spirit and principles of the present invention,
Modification, combination, simplifies substitution, is accordingly to be regarded as equivalent substitute mode, falls within the scope and spirit of the invention.
Embodiment
Experimental method used in following embodiments is such as conventional method without particular/special requirement.
Material as used in the following examples, reagent etc., are commercially available unless otherwise specified.
Embodiment 1
The first Sodium Hyaluronate that 0.05g molecular weight is 150KDa, second that 2g molecular weight is 1500KDa are weighed respectively
Kind of Sodium Hyaluronate, 5g histidine, 5gdl- alpha-tocopherol acetate, 0.5g calcium lactate, 0.1g histidine iron network chelate,
0.1g zinc gluconate, 0.05g copper sulphate, 0.03g manganese sulfate, 0.01g chromium citrate, 0.01g sodium selenite, 0.1g sulfuric acid
Magnesium, 0.05g potassium phosphate, 15g collagen, 5g gucosamine, 20 light dydrocarbon of 1g sodium chondroitin sulfate, 1g dimethyl sulfone and 1g
Olefin(e) acid is mixed evenly, and obtains the composition containing Sodium Hyaluronate, and the component of the embodiment is shown in Table 1.
Embodiment 2
The first Sodium Hyaluronate that 1.5g molecular weight is 20KDa, second that 0.05g molecular weight is 220KDa are weighed respectively
Kind of Sodium Hyaluronate, 3g methionine, 20g vitamin D, 3g calcium lactate, 1.5g histidine iron network chelate, 1g zinc gluconate,
0.5g copper sulphate, 0.5g manganese sulfate, 0.5g chromium citrate, 0.5g sodium selenite, 1g magnesium sulfate, 0.3g potassium phosphate, 15g collagen egg
White, 10g gucosamine, 6g sodium chondroitin sulfate, 20g dimethyl sulfone and 20g eicosapentaenoic acid are mixed evenly, and obtain
The composition containing Sodium Hyaluronate, the component of the embodiment are shown in Table 1.
Embodiment 3
The first Sodium Hyaluronate that 0.5g molecular weight is 30KDa, second that 1.5g molecular weight is 250KDa are weighed respectively
Kind of Sodium Hyaluronate, 10g arginine, 10g vitamin D, 1g calcium lactate, 1g histidine iron network chelate, 0.5g zinc gluconate,
0.1g copper sulphate, 0.2g manganese sulfate, 0.4g chromium citrate, 0.3g sodium selenite, 0.5g magnesium sulfate, 0.1g potassium phosphate, 15g collagen
Albumen, 6g gucosamine, 8g sodium chondroitin sulfate, 10g dimethyl sulfone and 10g eicosapentaenoic acid are mixed evenly, and obtain
To the composition containing Sodium Hyaluronate, the component of the embodiment is shown in Table 1.
Embodiment 4
The first Sodium Hyaluronate that 1g molecular weight is 40KDa, second that 0.05g molecular weight is 300KDa are weighed respectively
Sodium Hyaluronate, 1g hydroxyl methionine, 5gdl- alpha-tocopherol acetate, 10g vitamin D, 2g calcium lactate, 0.3g histidine iron network
Chelate, 0.3g zinc gluconate, 0.03g copper sulphate, 0.1g manganese sulfate, 0.1g chromium citrate, 0.1g sodium selenite, 0.3g sulphur
Sour magnesium, 0.2g potassium phosphate, 15g collagen, 8g gucosamine, 20 carbon of 5g sodium chondroitin sulfate, 5g dimethyl sulfone and 5g
Five olefin(e) acid is mixed evenly, and obtains the composition containing Sodium Hyaluronate, and the component of the embodiment is shown in Table 1.
Embodiment 5
The first Sodium Hyaluronate that 0.05g molecular weight is 50KDa, second that 0.2g molecular weight is 400KDa are weighed respectively
Kind Sodium Hyaluronate, 3g histidine, 5g methionine, 5gdl- alpha-tocopherol acetate, 5g vitamin D, 2g calcium lactate, 0.3g group
Propylhomoserin iron network chelate, 0.3g zinc gluconate, 0.03g copper sulphate, 0.1g manganese sulfate, 0.1g chromium citrate, 0.1g selenous acid
Sodium, 1g magnesium sulfate, 0.3g potassium phosphate, 15g collagen, 6g gucosamine, 5g sodium chondroitin sulfate, 3g dimethyl sulfone and 3g
Eicosapentaenoic acid is mixed evenly, and obtains the composition containing Sodium Hyaluronate, and the component of the embodiment is shown in Table 1.
Embodiment 6
The first Sodium Hyaluronate that 0.35g molecular weight is 60KDa, second that 0.8g molecular weight is 600KDa are weighed respectively
Kind Sodium Hyaluronate, 1g arginine, 8g methionine, 3gdl- alpha-tocopherol acetate, 8g vitamin D, 2g calcium lactate, 0.3g group
Propylhomoserin iron network chelate, 0.3g zinc gluconate, 0.03g copper sulphate, 0.1g manganese sulfate, 0.1g chromium citrate, 0.1g selenous acid
Sodium, 1g magnesium sulfate, 0.3g potassium phosphate, 30g collagen, 6g gucosamine, 5g sodium chondroitin sulfate, 8g dimethyl sulfone and 8g
Eicosapentaenoic acid is mixed evenly, and obtains the composition containing Sodium Hyaluronate, and the component of the embodiment is shown in Table 1.
Embodiment 7
The first Sodium Hyaluronate that 0.5g molecular weight is 20KDa, second that 1g molecular weight is 300KDa are weighed respectively
Sodium Hyaluronate, 1g histidine, 8g hydroxyl methionine, 4gdl- alpha-tocopherol acetate, 11g vitamin D, 2g calcium lactate, 0.3g group
Propylhomoserin iron network chelate, 0.3g zinc gluconate, 0.03g copper sulphate, 0.1g manganese sulfate, 0.1g chromium citrate, 0.1g selenous acid
Sodium, 1g magnesium sulfate, 0.3g potassium phosphate, 18g collagen, 6g gucosamine, 5g sodium chondroitin sulfate, 5g dimethyl sulfone and 5g
Eicosapentaenoic acid is mixed evenly, and obtains the composition containing Sodium Hyaluronate, and the component of the embodiment is shown in Table 1.
Embodiment 8
The first Sodium Hyaluronate that 2g molecular weight is 80KDa, second that 0.5g molecular weight is 600KDa are weighed respectively
Sodium Hyaluronate, 1g lysine, 8g methionine, 4gdl- alpha-tocopherol acetate, 11g vitamin D, 2g calcium lactate, 0.3g group ammonia
Sour iron network chelate, 0.3g zinc gluconate, 0.03g copper sulphate, 0.1g manganese sulfate, 0.1g chromium citrate, 0.1g sodium selenite,
1g magnesium sulfate, 0.3g potassium phosphate, 18g collagen, 6g gucosamine, 5g sodium chondroitin sulfate, 5g dimethyl sulfone and 5g bis-
Ten carbon 5 alkene acids are mixed evenly, and obtain the composition containing Sodium Hyaluronate, and the component of the embodiment is shown in Table 1.
Embodiment 9
The first Sodium Hyaluronate that 1.5g molecular weight is 60KDa, second that 0.2g molecular weight is 800KDa are weighed respectively
Kind Sodium Hyaluronate, 1g lysine, 5g methionine, 2g arginine, 5gdl- alpha-tocopherol acetate, 7g vitamin D, 2g lactic acid
Calcium, 0.3g histidine iron network chelate, 0.3g zinc gluconate, 0.03g copper sulphate, 0.1g manganese sulfate, 0.1g chromium citrate,
0.1g sodium selenite, 1g magnesium sulfate, 0.3g potassium phosphate, 20g collagen, 6g gucosamine, 5g sodium chondroitin sulfate, 5g diformazan
Base sulfone and 5g eicosapentaenoic acid are mixed evenly, and obtain the composition containing Sodium Hyaluronate, the group of the embodiment
Divide and is shown in Table 1.
Embodiment 10
The first Sodium Hyaluronate that 0.4g molecular weight is 80KDa, second that 0.9g molecular weight is 1000KDa are weighed respectively
Kind Sodium Hyaluronate, 2g histidine, 4g methionine, 2g arginine, 8gdl- alpha-tocopherol acetate, 5g vitamin D, 2g lactic acid
Calcium, 0.3g histidine iron network chelate, 0.3g zinc gluconate, 0.03g copper sulphate, 0.1g manganese sulfate, 0.1g chromium citrate,
0.1g sodium selenite, 1g magnesium sulfate, 0.3g potassium phosphate, 25g collagen, 6g gucosamine, 5g sodium chondroitin sulfate, 5g diformazan
Base sulfone and 5g eicosapentaenoic acid are mixed evenly, and obtain the composition containing Sodium Hyaluronate, the group of the embodiment
Divide and is shown in Table 1.
Comparative example 1
Weigh respectively 5g histidine, 5gdl- alpha-tocopherol acetate, 0.5g calcium lactate, 0.1g histidine iron network chelate,
0.1g zinc gluconate, 0.05g copper sulphate, 0.03g manganese sulfate, 0.01g chromium citrate, 0.01g sodium selenite, 0.1g sulfuric acid
Magnesium, 0.05g potassium phosphate, 15g collagen, 5g gucosamine, 20 light dydrocarbon of 1g sodium chondroitin sulfate, 5g dimethyl sulfone and 5g
Olefin(e) acid is mixed evenly, and obtains the composition for being free of Sodium Hyaluronate, and the component of the embodiment is shown in Table 1.
Comparative example 2
The first Sodium Hyaluronate, 5g histidine, the 5gdl- alpha-tocopherol acetic acid that 1g molecular weight is 50KDa are weighed respectively
Ester, 0.5g calcium lactate, 0.1g histidine iron network chelate, 0.1g zinc gluconate, 0.05g copper sulphate, 0.03g manganese sulfate,
0.01g chromium citrate, 0.01g sodium selenite, 0.1g magnesium sulfate, 0.05g potassium phosphate, 15g collagen, 5g gucosamine, 1g
Sodium chondroitin sulfate, 5g dimethyl sulfone and 5g eicosapentaenoic acid are mixed evenly, and obtain described containing Sodium Hyaluronate
The component of composition, the embodiment is shown in Table 1.
Comparative example 3
Second of Sodium Hyaluronate, 4g histidine, 2g arginine, the 5gdl- α-that 1g molecular weight is 1000KDa are weighed respectively
Tocopherol acetate, 0.5g calcium lactate, 0.1g histidine iron network chelate, 0.1g zinc gluconate, 0.05g copper sulphate, 0.03g
Manganese sulfate, 0.01g chromium citrate, 0.01g sodium selenite, 0.1g magnesium sulfate, 0.05g potassium phosphate, 15g collagen, 5g grape
Osamine, 1g sodium chondroitin sulfate, 5g dimethyl sulfone and 5g eicosapentaenoic acid are mixed evenly, and obtain described containing hyalomitome
The component of the composition of sour sodium, the embodiment is shown in Table 1.
Comparative's table of each embodiment of table 1
Effect test
Zoopery
1. experimental method:
The ablactation SD rat of birth surrounding is chosen, SPF grades, female, 66-78g, 360, wherein every group 120, and it is each
Each embodiment 10 in group, using sample of the present invention feed rat, ends in 10 weeks execution, measure rat body weight, femur dry weight,
The indexs such as bone density, calcium content of bone.Separately set calcium carbonate control group (calcium content is identical as high dose group) and low calcium control group.
2. tested material manner of formulation:
The composition provided in 1- of embodiment of the present invention embodiment 10 and comparative example 1- comparative example 3 is provided respectively, add from
Sub- water is to 30ml, by this ratio uniform mixed preparing test liquid.
3. tested material gives mode:
To sample, stomach-filling capacity is 10ml/kgBW for stomach-filling.
4. experimental result
A. given the test agent influences rat body weight:
Each experimental group given the test agent of table 2. influences rat body weight
As shown in Table 2, the composition according to the present invention compounded containing Sodium Hyaluronate, is conducive to the growth of rat,
And embodiment 4- embodiment 7, i.e. the first Sodium Hyaluronate of 20KDa-60KDa and second of hyalomitome of 300KDa-600KDa
The composition of sour sodium compounding, it is best for the growth result of rat.
B. influence of the given the test agent to the weight, bone calcium and femoral bmd of rat femur:
Influence of the sample of the invention of table 3. to the weight of femur, bone calcium and bone density
As shown in Table 3, the composition according to the present invention compounded containing Sodium Hyaluronate is conducive to the bone for improving rat
Second of density, especially embodiment 4- embodiment 7, i.e. the first Sodium Hyaluronate of 20KDa-60KDa and 300KDa-600KDa are thoroughly
The composition of bright matter acid sodium compounding, it is best for the bone mineral density effect of rat.
C. influence of the given the test agent to rat calcium metabolism:
Influence of the sample of the invention of table 4. to calcium metabolism in rat experiment periods
As shown in Table 4, the composition according to the present invention compounded containing Sodium Hyaluronate is conducive to the growth hair of rat
The absorption with calcium is educated, especially embodiment 4- embodiment 7 is the first Sodium Hyaluronate of 20KDa-60KDa and 300KDa-600KDa
The composition of second of Sodium Hyaluronate compounding, the assimilation effect of growth and development and calcium for rat are best.
To sum up, the composition provided by the invention containing Sodium Hyaluronate, it is saturating using the first Sodium Hyaluronate and second
Bright matter acid sodium compounding is used as main component, the Sodium Hyaluronate can fine lubricating joint, cooperate amino acid, vitamin, mine
Matter-element element and its complex compound, protein, gucosamine, sodium chondroitin sulfate, dimethyl sulfone and eicosapentaenoic acid, so that institute
It states composition and integrates and replenish the calcium and joint protection, to arthritis, joint motions are impaired good prevention effect, while can also
Promote development, enhancing bone density, improves the toughness and hardness of bone.
Claims (10)
1. a kind of composition containing Sodium Hyaluronate, which is characterized in that saturating for the first of 20KDa-150KDa comprising molecular weight
Bright matter acid sodium, second of Sodium Hyaluronate, amino acid and the vitamin that molecular weight is 220KDa-1500KDa.
2. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that the first described Sodium Hyaluronate
Molecular weight be 20KDa-100KDa；Preferably, the molecular weight of the first Sodium Hyaluronate is 20KDa-80KDa；Into one
Preferably, the molecular weight of the first Sodium Hyaluronate is 20KDa-60KDa to step.
3. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that second of Sodium Hyaluronate
Molecular weight be 250KDa-1000KDa；Preferably, the molecular weight of second of Sodium Hyaluronate is 250KDa-800KDa；
It is further preferred that the molecular weight of second of Sodium Hyaluronate is 300KDa-600KDa.
4. the composition according to claim 2 or 3 containing Sodium Hyaluronate, which is characterized in that relative to 100 weight of total weight
The total content of the composition of amount part, the first described Sodium Hyaluronate and second of Sodium Hyaluronate is 0.1-4 parts.
5. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that relative to 100 weight of total weight
The composition of part, the content of the first Sodium Hyaluronate are 0.05-2 parts；Preferably, the first Sodium Hyaluronate
Content is 0.05-1.5 parts；It is further preferred that the content of the first Sodium Hyaluronate is 0.05-1 parts.
6. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that relative to 100 weight of total weight
The composition of part, the content of second of Sodium Hyaluronate are 0.05-2 parts, it is preferable that second of Sodium Hyaluronate
Content is 0.05-1.5 parts；It is further preferred that the content of second of Sodium Hyaluronate is 0.05-1 parts.
7. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that the composition further includes albumen
Matter, gucosamine, sodium chondroitin sulfate, dimethyl sulfone and eicosapentaenoic acid；Combination relative to 100 parts by weight of total weight
Object, the content of the protein are 15-30 parts, and the content of the gucosamine is 5-10 parts, and the sodium chondroitin sulfate contains
Amount is 1-20 parts, and dimethyl sulfone is 1-15 parts and eicosapentaenoic acid is 1-20 parts.
8. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that the amino acid is selected from group ammonia
At least one of acid, methionine, hydroxyl methionine, lysine or arginine；Combination relative to 100 parts by weight of total weight
Object, the total content of the amino acid are 1-10 parts.
9. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that the vitamin is selected from dl- α-
At least one of tocopherol acetate or vitamin D；Relative to the composition of 100 parts by weight of total weight, the vitamin
Total content is 5-20 parts.
10. the composition according to claim 1 containing Sodium Hyaluronate, which is characterized in that the composition further includes mine
Matter-element element and its complex compound, relative to the composition of 100 parts by weight of total weight, the mineral element and its complex compound include:
0.5-3 parts of calcium lactates, 0.1-1 parts of magnesium sulfate, 0.1-1.5 parts of histidine iron network chelates, 0.1-1 parts of zinc gluconates, 0.05-
0.5 part of copper sulphate, 0.05-0.3 parts of potassium phosphates, 0.03-0.5 parts of manganese sulfates, 0.01-0.5 parts of chromium citrates and 0.01-0.5
Part sodium selenite.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910252713.XA CN109965104A (en) | 2019-03-29 | 2019-03-29 | A kind of composition and its preparation method and application containing Sodium Hyaluronate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910252713.XA CN109965104A (en) | 2019-03-29 | 2019-03-29 | A kind of composition and its preparation method and application containing Sodium Hyaluronate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109965104A true CN109965104A (en) | 2019-07-05 |
Family
ID=67081919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910252713.XA Pending CN109965104A (en) | 2019-03-29 | 2019-03-29 | A kind of composition and its preparation method and application containing Sodium Hyaluronate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109965104A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140312A (en) * | 1992-02-20 | 2000-10-31 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US20080069862A1 (en) * | 2006-09-15 | 2008-03-20 | Marni Markell Hurwitz | Joint preserving nutritional vitamin, mineral and herbal pet supplement |
| CN101248882A (en) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | Nutrition food product with promoting health of bones and bone arthrosis |
| CN102894372A (en) * | 2012-11-05 | 2013-01-30 | 江苏江大源生态生物科技有限公司 | Health-care food for increasing bone density and preparation method thereof |
| CN103255187A (en) * | 2012-02-21 | 2013-08-21 | 华熙福瑞达生物医药有限公司 | Low molecular hyaluronate, preparation method and purpose thereof |
| WO2014044808A2 (en) * | 2012-09-21 | 2014-03-27 | Labo Cosprophar Ag | Fast-penetration cosmetic dermal filler for topical application |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN104645332A (en) * | 2015-03-06 | 2015-05-27 | 江苏正大清江制药有限公司 | Pharmaceutical composition for relieving and preventing arthritis |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| US20180289735A1 (en) * | 2009-07-23 | 2018-10-11 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain using hyaluronic acid and eggshell membrane components |
| CN108635247A (en) * | 2018-06-27 | 2018-10-12 | 广州澳希亚实业有限公司 | Cosmetic composition containing sodium hyaluronate |
| CN108721320A (en) * | 2017-04-24 | 2018-11-02 | 惠觅宙 | The application of micromolecule hyaluronic acid segment |
| CN109330912A (en) * | 2018-12-10 | 2019-02-15 | 安徽徽科生物工程技术有限公司 | Beautifying skin remediation composition and facial mask |
-
2019
- 2019-03-29 CN CN201910252713.XA patent/CN109965104A/en active Pending
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140312A (en) * | 1992-02-20 | 2000-10-31 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US20080069862A1 (en) * | 2006-09-15 | 2008-03-20 | Marni Markell Hurwitz | Joint preserving nutritional vitamin, mineral and herbal pet supplement |
| CN101248882A (en) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | Nutrition food product with promoting health of bones and bone arthrosis |
| US20180289735A1 (en) * | 2009-07-23 | 2018-10-11 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain using hyaluronic acid and eggshell membrane components |
| CN103255187A (en) * | 2012-02-21 | 2013-08-21 | 华熙福瑞达生物医药有限公司 | Low molecular hyaluronate, preparation method and purpose thereof |
| WO2014044808A2 (en) * | 2012-09-21 | 2014-03-27 | Labo Cosprophar Ag | Fast-penetration cosmetic dermal filler for topical application |
| CN102894372A (en) * | 2012-11-05 | 2013-01-30 | 江苏江大源生态生物科技有限公司 | Health-care food for increasing bone density and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN104645332A (en) * | 2015-03-06 | 2015-05-27 | 江苏正大清江制药有限公司 | Pharmaceutical composition for relieving and preventing arthritis |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| CN108721320A (en) * | 2017-04-24 | 2018-11-02 | 惠觅宙 | The application of micromolecule hyaluronic acid segment |
| CN108635247A (en) * | 2018-06-27 | 2018-10-12 | 广州澳希亚实业有限公司 | Cosmetic composition containing sodium hyaluronate |
| CN109330912A (en) * | 2018-12-10 | 2019-02-15 | 安徽徽科生物工程技术有限公司 | Beautifying skin remediation composition and facial mask |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7799348B2 (en) | Therapeutic composition comprising hyaluronic acid and chondroitin sulfate and method of making same | |
| US5198465A (en) | Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen | |
| KR101075816B1 (en) | Total enteral nutritious composition | |
| RU2001110097A (en) | THERAPEUTIC COMPOSITIONS (II) | |
| KR100828494B1 (en) | A composition of a cosmetic essense and the method of prepating it for improvenent of wrinkle | |
| CN101693108A (en) | Oral nutrition composition for beautifying skin | |
| CN113679046B (en) | Composition for promoting interaction of hyaluronic acid and collagen and application thereof | |
| CN109090443A (en) | It is a kind of to replenish the calcium the nutrition formula product of strong bone function with lock calcium | |
| KR101161634B1 (en) | Method for producing antler ferment solution with enhanced specific free amino acids content and antler ferment solution produced by the same method | |
| KR20100039874A (en) | New use of known pharmacologically active chemical compounds | |
| CN1237910C (en) | Whole nutrient powder and its production method | |
| CN114557448A (en) | Preparation easy to be absorbed by human body and capable of improving human cartilage tissue and preparation method | |
| CN109965104A (en) | A kind of composition and its preparation method and application containing Sodium Hyaluronate | |
| TWI830696B (en) | Compositions for inhibiting muscle fiber degeneration | |
| JP2002125662A (en) | Non-deactivated enzyme-reinforced composition | |
| CN101690591A (en) | Yak marrow polypeptide bone growing and height increasing tablets (powder) | |
| Stewart | Bone Pathology in Experimental Malnutrition1 | |
| JP2004229534A (en) | Hydrolyzed eggshell membrane-containing drink | |
| CN108815505B (en) | Composition for improving bone density and bone joint function of middle-aged and elderly people and avoiding lumbar and leg cramps | |
| MXPA05004994A (en) | Composition for the treatment of gastrointestinal disorders. | |
| CN115153033A (en) | Compound small molecule peptide formula for conditioning body nutrition imbalance | |
| CN103005211A (en) | Application of calcium-chitosan organic calcium supplement to animal feed | |
| CN101536788A (en) | Calcium supply oral liquid for old people | |
| EP3756477A1 (en) | Nano collagen peptide chelate mineral and method for preparing the same | |
| WO2005079602A1 (en) | Food supplement composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230608 Address after: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Applicant after: BLOOMAGE BIOTECH Co.,Ltd. Address before: No. 678, Tianchen street, high tech Zone, Jinan City, Shandong Province Applicant before: BLOOMAGE BIOTECH Co.,Ltd. Applicant before: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |